Clinical Trial

Intranasal Corticosteroid Spray for Preventing Otitis Media With Effusion After Radiotherapy in Nasopharyngeal Carcinoma

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study focuses on a common side effect experienced by many patients after radiation therapy for nasopharyngeal cancer, which is a type of head and neck cancer. This side effect is called secretory otitis media (fluid buildup in the middle ear). It can cause a feeling of fullness in the ear and hearing loss. While procedures like ear tube placement can help, they can also lead to other problems like ear infections and drainage. Radiation treatment is thought to cause inflammation that disrupts the normal function of the tube connecting the ear to the throat (Eustachian tube), leading to this fluid buildup. A nasal spray containing a steroid medicine (triamcinolone acetonide) is already known to be safe and effective at reducing inflammation in the ear fluid of both children and adults. We believe that using this spray may also help prevent and improve this condition in nasopharyngeal cancer patients after radiation therapy. The main goal of this study is to explore whether this nasal spray can effectively prevent or reduce fluid buildup in the ear following radiation therapy. We hope this non-invasive treatment will provide a new option to improve the quality of life for these patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-16.
Trial Details
NCT Number NCT07189572
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Sun Yat-Sen University Cancer Center, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Otitis Media, Otitis Media With Effusion After Nasopharyngeal Carcinoma, Radiotherapy Side Effects, Radiotherapy Side Effect, Otitis Media With Effusion (OME)
Enrollment 168 participants
Start Date 2025-10
Primary Completion 2027-08 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2025-09-29